PubMed:33152616 / 1122-1690
Annnotations
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 0-568 | Sentence | denotes | The results shows HIV-protease inhibitors such as cobicistat (-8.3kcal/mol), Darunavir (-7.4kcal/mol), Lopinavir (-9.1kcal/mol) and Ritonavir (-8.0 kcal/mol), anti-inflammatory drugs such as Baricitinib (-5.8kcal/mol), Ruxolitinib (-6.5kcal/mol), Thalidomide (-6.5kcal/mol), antibiotic drugs such as Erythromycin(-9.0kcal/mol) and Spiramycin (-8.5kcal/mol) molecules have good affinity towards spike protein compared to antimalarial drugs Chloroquine (-6.2kcal/mol), Hydroxychloroquine (-5.2kcal/mol) and Artemisinin (-6.8kcal/mol) have poor affinity to spike protein. |
T9 | 0-568 | Sentence | denotes | The results shows HIV-protease inhibitors such as cobicistat (-8.3kcal/mol), Darunavir (-7.4kcal/mol), Lopinavir (-9.1kcal/mol) and Ritonavir (-8.0 kcal/mol), anti-inflammatory drugs such as Baricitinib (-5.8kcal/mol), Ruxolitinib (-6.5kcal/mol), Thalidomide (-6.5kcal/mol), antibiotic drugs such as Erythromycin(-9.0kcal/mol) and Spiramycin (-8.5kcal/mol) molecules have good affinity towards spike protein compared to antimalarial drugs Chloroquine (-6.2kcal/mol), Hydroxychloroquine (-5.2kcal/mol) and Artemisinin (-6.8kcal/mol) have poor affinity to spike protein. |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T8 | 18-21 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
T9 | 400-407 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T10 | 560-567 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T27 | 18-41 | Chemical | denotes | HIV-protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_35660 |
T28 | 22-41 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T30 | 31-41 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T31 | 50-60 | Chemical | denotes | cobicistat | http://purl.obolibrary.org/obo/CHEBI_72291 |
T32 | 77-86 | Chemical | denotes | Darunavir | http://purl.obolibrary.org/obo/CHEBI_367163 |
T33 | 103-112 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T34 | 159-182 | Chemical | denotes | anti-inflammatory drugs | http://purl.obolibrary.org/obo/CHEBI_35472 |
T35 | 177-182 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T36 | 247-258 | Chemical | denotes | Thalidomide | http://purl.obolibrary.org/obo/CHEBI_9513 |
T37 | 275-285 | Chemical | denotes | antibiotic | http://purl.obolibrary.org/obo/CHEBI_33281 |
T38 | 286-291 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T39 | 300-312 | Chemical | denotes | Erythromycin | http://purl.obolibrary.org/obo/CHEBI_42355 |
T40 | 331-341 | Chemical | denotes | Spiramycin | http://purl.obolibrary.org/obo/CHEBI_85260 |
T41 | 357-366 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
T42 | 400-407 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T43 | 420-432 | Chemical | denotes | antimalarial | http://purl.obolibrary.org/obo/CHEBI_38068 |
T44 | 433-438 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T45 | 439-450 | Chemical | denotes | Chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T46 | 560-567 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
22 | 103-112 | Chemical | denotes | Lopinavir | MESH:D061466 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 0-568 | Sentence | denotes | The results shows HIV-protease inhibitors such as cobicistat (-8.3kcal/mol), Darunavir (-7.4kcal/mol), Lopinavir (-9.1kcal/mol) and Ritonavir (-8.0 kcal/mol), anti-inflammatory drugs such as Baricitinib (-5.8kcal/mol), Ruxolitinib (-6.5kcal/mol), Thalidomide (-6.5kcal/mol), antibiotic drugs such as Erythromycin(-9.0kcal/mol) and Spiramycin (-8.5kcal/mol) molecules have good affinity towards spike protein compared to antimalarial drugs Chloroquine (-6.2kcal/mol), Hydroxychloroquine (-5.2kcal/mol) and Artemisinin (-6.8kcal/mol) have poor affinity to spike protein. |